Literature DB >> 22223820

Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.

Shinobu Matsuura1, Ming Yan, Miao-Chia Lo, Eun-Young Ahn, Stephanie Weng, David Dangoor, Mahan Matin, Tsunehito Higashi, Gen-Sheng Feng, Dong-Er Zhang.   

Abstract

The t(8;21)(q22;q22) is common in adult acute myeloid leukemia (AML). The RUNX1-ETO fusion protein that is expressed by this translocation is poorly leukemogenic and requires additional mutations for transformation. Loss of sex chromosome (LOS) is frequently observed in t(8;21) AML. In the present study, to evaluate whether LOS cooperates with t(8;21) in leukemogenesis, we first used a retroviral transduction/transplantation model to express RUNX1-ETO in hematopoietic cells from XO mice. The low frequency of leukemia in these mice suggests that the potentially critical gene for suppression of t(8;21) leukemia in humans is not conserved on mouse sex chromosomes. The gene encoding the GM-CSF receptor α subunit (CSF2RA) is located on X and Y chromosomes in humans but on chromosome 19 in mice. GM-CSF promotes myeloid cell survival, proliferation, and differentiation. To determine whether GM-CSF signaling affects RUNX1-ETO leukemogenesis, hematopoietic stem/progenitor cells that lack GM-CSF signaling were used to express RUNX1-ETO and transplanted into lethally irradiated mice, and a high penetrance of AML was observed in recipients. Furthermore, GM-CSF reduced the replating ability of RUNX1-ETO-expressing cells. These results suggest a possible tumor-suppressor role of GM-CSF in RUNX1-ETO leukemia. Loss of the CSF2RA gene may be a critical mutation explaining the high incidence of LOS associated with the t(8;21)(q22;q22) translocation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223820      PMCID: PMC3321875          DOI: 10.1182/blood-2011-04-350694

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  A high frequency of XO offspring from X(Paf)Y* male mice: evidence that the Paf mutation involves an inversion spanning the X PAR boundary.

Authors:  P S Burgoyne; E P Evans
Journal:  Cytogenet Cell Genet       Date:  2000

2.  Comparison of the hematopoietic activity of flt-3 ligand and granulocyte-macrophage colony-stimulating factor acting alone or in combination.

Authors:  S Robinson; R L Mosley; P Parajuli; V Pisarev; J Sublet; A Ulrich; J Talmadge
Journal:  J Hematother Stem Cell Res       Date:  2000-10

3.  Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia.

Authors:  Jorg Basecke; Lukas Cepek; Christine Mannhalter; Jurgen Krauter; Stefanie Hildenhagen; Guenter Brittinger; Lorenz Trumper; Frank Griesinger
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

4.  The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.

Authors:  James C Mulloy; Jörg Cammenga; Karen L MacKenzie; Francisco J Berguido; Malcolm A S Moore; Stephen D Nimer
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

5.  Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.

Authors:  G Jahns-Streubel; J Braess; C Schoch; C Fonatsch; D Haase; C Binder; B Wörmann; T Büchner; W Hiddemann
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

6.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.

Authors:  Y Yuan; L Zhou; T Miyamoto; H Iwasaki; N Harakawa; C J Hetherington; S A Burel; E Lagasse; I L Weissman; K Akashi; D E Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

7.  Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.

Authors:  K L Rhoades; C J Hetherington; N Harakawa; D A Yergeau; L Zhou; L Q Liu; M T Little; D G Tenen; D E Zhang
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

8.  Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.

Authors:  Cristina G de Guzman; Alan J Warren; Zheng Zhang; Larry Gartland; Paul Erickson; Harry Drabkin; Scott W Hiebert; Christopher A Klug
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

9.  Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

Authors:  Scott C Kogan; Jerrold M Ward; Miriam R Anver; Jules J Berman; Cory Brayton; Robert D Cardiff; John S Carter; Sherri de Coronado; James R Downing; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy Lee Harris; Hiroshi Hiai; Elaine S Jaffe; Ian C M MacLennan; Pier Paolo Pandolfi; Paul K Pattengale; Archibald S Perkins; R Mark Simpson; Mark S Tuttle; Joanne F Wong; Herbert C Morse
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

10.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.

Authors:  Masakazu Higuchi; Darin O'Brien; Parasakthy Kumaravelu; Noel Lenny; Eng-Juh Yeoh; James R Downing
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  7 in total

1.  Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.

Authors:  Jingfang Zhang; Erik A Ranheim; Juan Du; Yangang Liu; Jinyong Wang; Guangyao Kong; Jing Zhang
Journal:  J Biol Chem       Date:  2015-06-16       Impact factor: 5.157

Review 2.  RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia.

Authors:  Emiel van der Kouwe; Philipp Bernhard Staber
Journal:  Int J Mol Sci       Date:  2019-01-16       Impact factor: 5.923

3.  Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis.

Authors:  Qi Zhang; Lei Zhao; Yi Yang; Shujun Li; Yu Liu; Chong Chen
Journal:  JCI Insight       Date:  2022-02-08

4.  Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity.

Authors:  S Weng; S Matsuura; C T Mowery; S A Stoner; K Lam; D Ran; A G Davis; M-C Lo; D-E Zhang
Journal:  Leukemia       Date:  2016-06-15       Impact factor: 11.528

Review 5.  Sex chromosome loss and the pseudoautosomal region genes in hematological malignancies.

Authors:  Stephanie Weng; Samuel A Stoner; Dong-Er Zhang
Journal:  Oncotarget       Date:  2016-11-01

Review 6.  Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation.

Authors:  Julia K Bialek-Waldmann; Michael Heuser; Arnold Ganser; Renata Stripecke
Journal:  Cancer Immunol Immunother       Date:  2019-10-18       Impact factor: 6.968

7.  Functional annotation of noncoding mutations in cancer.

Authors:  Husen M Umer; Karolina Smolinska; Jan Komorowski; Claes Wadelius
Journal:  Life Sci Alliance       Date:  2021-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.